Lixisenatide as add-on therapy to basal insulin

References

• Holst JJ Vilsboll T Deacon CF The incretin system and its role in type 2 diabetes mellitus Mol Cell Endocrinol 2009 297 1–2 127 136 18786605
   PubMed Web of Science ®Google Scholar
• Knop FK Vilsboll T Hojberg PV Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007 56 8 1951 1959 17513701
   PubMed Web of Science ®Google Scholar
• McIntyre N Holdsworth CD Turner DS New interpretation of oral glucose tolerance Lancet 1964 2 7349 20 21 14149200
   PubMed Web of Science ®Google Scholar
• Perry T Greig NH The glucagon-like peptides: a double-edged therapeutic sword? Trends Pharmacol Sci 2003 24 7 377 383 12871671
   PubMed Web of Science ®Google Scholar
• Drucker DJ Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006 368 9548 1696 1705 17098089
   PubMed Web of Science ®Google Scholar
• Neumiller JJ Setter SM Review of linagliptin for the treatment of type 2 diabetes mellitus Clin Ther 2012 34 5 993 1005 22440191
   PubMed Web of Science ®Google Scholar
• Barnett A DPP-4 inhibitors and their potential role in the management of type 2 diabetes Int J Clin Pract 2006 60 11 1454 1470 17073841
   PubMed Web of Science ®Google Scholar
• Nathan DM Buse JB Davidson MB Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2009 32 1 193 203 18945920
   PubMed Web of Science ®Google Scholar
• Morales J The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors Postgrad Med 2011 123 6 189 201 22104467
   PubMed Web of Science ®Google Scholar
• Elkinson S Keating GM Lixisenatide: first global approval Drugs 2013 73 4 383 391 23558600
   PubMed Web of Science ®Google Scholar
• Kim D Wang L Beconi M (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J Med Chem 2005 48 1 141 151 15634008
   PubMed Web of Science ®Google Scholar
• Augeri DJ Robl JA Betebenner DA Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J Med Chem 2005 48 15 5025 5037 16033281
   PubMed Web of Science ®Google Scholar
• Villhauer EB Brinkman JA Naderi GB 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties J Med Chem 2003 46 13 2774 2789 12801240
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence NICE Clinical Guideline 87. The management of type 2 diabetes 2011 Available from: http://www.nice.org.uk/nicemedia/live/12165/44320/44320.pdf Accessed November 6, 2013
   Google Scholar
• DeFronzo RA Okerson T Viswanathan P Guan X Holcombe JH MacConell L Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study Curr Med Res Opin 2008 24 10 2943 2952 18786299
   PubMed Web of Science ®Google Scholar
• Thong KY Jose B Sukumar N Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit* Diabetes Obes Metab 2011 13 8 703 710 21410858
   PubMed Web of Science ®Google Scholar
• Buse JB Bergenstal RM Glass LC Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial Ann Intern Med 2011 154 2 103 112 21138825
   PubMed Web of Science ®Google Scholar
• DeVries JH Bain SC Rodbard HW Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1c targets Diabetes Care 2012 35 7 1446 1454 22584132
   PubMed Web of Science ®Google Scholar
• European Medicines Agency Summary of product characteristics: Exenatide 2012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000698/WC500051845.pdf Accessed February 7, 2012
   Google Scholar
• European Medicines Agency Summary of product characteristics: Bydureon 2012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002020/WC500108241.pdf Accessed February 7, 2012
   Google Scholar
• Food and Drug Administration Drug details: Victoza 2013 Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails Accessed February 8, 2013
   Google Scholar
• European Medicines Agency Summary of product characteristics: Liraglutide 2012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdf Accessed February 7, 2012
   Google Scholar
• Monnier L Colette C Boniface H Contribution of postprandial glucose to chronic hyperglycaemia: from the glucose triad to the trilogy of “sevens” Diabetes Metab 2006 32 Spec 2 2S11 S16 17375401
   PubMed Web of Science ®Google Scholar
• Monnier L Colette C Contributions of fasting and postprandial glucose to hemoglobin A1c Endocr Pract 2006 12 Suppl 1 42 46 16627379
   PubMedGoogle Scholar
• Barnett AH Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes Core Evid 2011 6 67 79 22022289
   PubMedGoogle Scholar
• European Medicines Agency Summary of product characteristics: Lyxumia 2012 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002445/smops/Positive/human_smop_000448.jsp&mid=WC0b01ac058001d127 Accessed February 1, 2013
   Google Scholar
• National Institute for Clinical Excellence NICE CG87 2013 Available from: http://www.nice.org.uk/nicemedia/pdf/CG87QuickRefGuide.pdf Accessed May 6, 2013
   Google Scholar
• Christensen M Knop FK Holst JJ Vilsboll T Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus IDrugs 2009 12 8 503 513 19629885
   PubMed Web of Science ®Google Scholar
• Christensen M Knop FK Vilsboll T Holst JJ Lixisenatide for type 2 diabetes mellitus Expert Opin Investig Drugs 2011 20 4 549 557
   PubMed Web of Science ®Google Scholar
• Buse JB Rosenstock J Sesti G Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 2009 374 9683 39 47 19515413
   PubMed Web of Science ®Google Scholar
• Lorenz M Pfeiffer C Steinstrasser A Ruus P Becker RH Effects of lixisenatide once daily on gastric emptying and its relationship to postprandial glycaemia in type 2 diabetes mellitus Poster 1085-P presented at the 72nd Scientific Sessions of the American Diabetes Association June 8–12, 2012 Philadelphia, PA, USA
   Google Scholar
• Bolli G Munteanu M Dotsenko S Niemoeller E Boka G Hanefeld M Efficacy and safety of lixisenatide once-daily versus placebo in patients with T2DM insufficiently controlled on metformin (GetGoal-F1) Diabetes Care 2011 54 Suppl 1 A784
   Google Scholar
• Monnier L Colette C Dunseath GJ Owens DR The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes Diabetes Care 2007 30 2 263 269 17259492
   PubMed Web of Science ®Google Scholar
• Kapitza C Forst T Coester HV Poitiers F Ruus P Hincelin-Mery A Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin Diabetes Obes Metab 2013 15 7 642 649 23368510
   PubMed Web of Science ®Google Scholar
• Riddle M Umpierrez G DiGenio A Zhou R Rosenstock J Contributions of basal and postprandial hyperglycemia over a wide range of A1c levels before and after treatment intensification in type 2 diabetes Diabetes Care 2011 34 12 2508 2514 22028279
   PubMed Web of Science ®Google Scholar
• Monnier L Lapinski H Colette C Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c) Diabetes Care 2003 26 3 881 885 12610053
   PubMed Web of Science ®Google Scholar
• Monnier L Colette C Owens D Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts Diabetes Technol Ther 2011 13 Suppl 1 S25 S32 21668334
   PubMed Web of Science ®Google Scholar
• Schernthaner G Guerci B Gallwitz B Impact of postprandial and fasting glucose concentrations on HbA1c in patients with type 2 diabetes Diabetes Metab 2010 36 5 389 394 20598608
   PubMed Web of Science ®Google Scholar
• Landgraf R The relationship of postprandial glucose to HbA1c Diabetes Metab Res Rev 2004 20 Suppl 2 S9 S12 15551296
   PubMed Web of Science ®Google Scholar
• Sloop KW Willard FS Brenner MB Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets Diabetes 2010 59 12 3099 3107 20823098
   PubMed Web of Science ®Google Scholar
• Kim YW Kim KH Choi HJ Lee DS Anti-diabetic activity of beta-glucans and their enzymatically hydrolyzed oligosaccharides from Agaricus blazei Biotechnol Lett 2005 27 7 483 487 15928854
   PubMed Web of Science ®Google Scholar
• Panahi S Ezatagha A Temelli F Vasanthan T Vuksan V Betaglucan from two sources of oat concentrates affect postprandial glycemia in relation to the level of viscosity J Am Coll Nutr 2007 26 6 639 644 18187427
   PubMed Web of Science ®Google Scholar
• Meier JJ GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus Nat Rev Endocrinol 2012 8 12 728 742 22945360
   PubMed Web of Science ®Google Scholar
• Cervera A Wajcberg E Sriwijitkamol A Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes Am J Physiol Endocrinol Metab 2008 294 5 E846 E852 18334612
   PubMed Web of Science ®Google Scholar
• Linnebjerg H Park S Kothare PA Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes Regul Pept 2008 151 1–3 123 129 18675854
   PubMedGoogle Scholar
• Su G Mi S Tao H Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes Cardiovasc Diabetol 2011 10 19 21349201
   PubMed Web of Science ®Google Scholar
• Ratner RE Hanefeld M Shamanna P Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on sulfonylurea ± metformin (GetGoal-S) Diabetologia 2011 54 Suppl 1 A785
   Google Scholar
• Pinget M Goldenberg R Niemoeller E Muehlen-Bartmer I Aronson R Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on pioglitazone. (GetGoal-P) Poster 1010-P presented at the 72nd Scientific Sessions of the American Diabetes Association June 8–12, 2012 Philadelphia, PA, USA
   Google Scholar
• Rosenstock J Raccah D Koranyi L Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X) Diabetes Care 2013 36 10 2945 2951 23698396
   PubMed Web of Science ®Google Scholar
• Riddle MC Forst T Aronson R Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1) Diabetes Care 2013 36 9 2497 2503 23564915
   PubMed Web of Science ®Google Scholar
• Riddle MC Aronson R Home P Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L) Diabetes Care 2013 36 9 2489 2496 23628617
   PubMed Web of Science ®Google Scholar
• Seino Y Min KW Niemoeller E Takami A EFC10887 GETGOAL-L Asia Study Investigators Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia) Diabetes Obes Metab 2012 14 10 910 917 22564709
   PubMed Web of Science ®Google Scholar
• Yabe D Seino Y Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and beta cell preservation Prog Biophys Mol Biol 2011 107 2 248 256 21820006
   PubMed Web of Science ®Google Scholar
• Yabe D Kuroe A Lee S Little enhancement of meal-induced glucagon-like peptide1secretion in Japanese: comparison of type 2 diabetes patients and healthy controls J Diabetes Investig 2010 1 1–2 56 59
   PubMed Web of Science ®Google Scholar
• Yabe D Watanabe K Sugawara K Comparison of incretin immu noassays with or without plasma extraction: incretin secretion in Japanese patients with type 2 diabetes J Diabetes Investig 2012 3 1 70 79
   PubMed Web of Science ®Google Scholar
• Fineman MS Cirincione BB Maggs D Diamant M GLP-1 based therapies: differential effects on fasting and postprandial glucose Diabetes Obes Metab 2012 14 8 675 688 22233527
   PubMed Web of Science ®Google Scholar
• Raccah D Miossec P Esposito V Niemoeller E Cho M Gerich JE Efficacy and safety of lixisenatide in elderly ($65 yr) and very elderly ($75 yr) patients with type 2 diabetes: an analysis from the GetGoal Phase 3 program Poster P972 presented at the 72nd Scientific Sessions of the American Diabetes Association June 8–12, 2012 Philadelphia, PA, USA
   Google Scholar
• Hegedus L Moses AC Zdravkovic M Le Thi T Daniels GH GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide J Clin Endocrinol Metab 2011 96 3 853 860 21209033
   PubMed Web of Science ®Google Scholar
• Crespel A De Boisvilliers F Gros L Kervran A Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line Endocrinology 1996 137 9 3674 3680 8756532
   PubMed Web of Science ®Google Scholar
• Bulchandani D Nachnani JS Herndon B Effect of exendin (exenatide) – GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model Eur J Pharmacol 2012 691 1–3 292 296 22819704
   PubMed Web of Science ®Google Scholar
• Madsen LW Knauf JA Gotfredsen C GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation Endocrinology 2012 153 3 1538 1547 22234463
   PubMed Web of Science ®Google Scholar
• Naslund E Bogefors J Skogar S GLP-1slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans Am J Physiol 1999 277 3 Pt 2 R910 R916 10484511
   PubMedGoogle Scholar
• Campbell RK Cobble ME Reid TS Shomali ME Distinguishing among incretin-based therapies. Safety, tolerability, and nong lycemic effects of incretin-based therapies J Fam Pract 2010 59 9 Suppl 1 S20 S27 20824236
   PubMed Web of Science ®Google Scholar
• Su G Mi SH Tao H Impact of admission glycemic variability, glucose, and glycosylated hemoglobin on major adverse cardiac events after acute myocardial infarction Diabetes Care 2013 36 4 1026 1032 23349547
   PubMed Web of Science ®Google Scholar
• Hu Y Liu W Huang R Zhang X Postchallenge plasma glucose excursions, carotid intima-media thickness, and risk factors for atherosclerosis in Chinese population with type 2 diabetes Atherosclerosis 2010 210 1 302 306 20005514
   PubMed Web of Science ®Google Scholar
• Lachin JM Genuth S Nathan DM Zinman B Rutledge BN Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial – revisited Diabetes 2008 57 4 995 1001 18223010
   PubMed Web of Science ®Google Scholar
• Clinical Trials.gov Evaluation of cardiovascular outcomes in patients with type 2 diabetes after acute coronary syndrome during treat ment with AVE0010 (lixisenatide) (ELIXA) Available from: http://clinicaltrials.gov/show/NCT01147250 Accessed April 15, 2013
   Google Scholar
• Sanofi Sanofi provides update on lixisenatide new drug application in US Available from: http://www.sanofi.dk/l/dk/da/download.jsp?file=5DDB9554-F37A-40D9-A1F3-C91F7BE06C9B.pdf Accessed October 27, 2013
   Google Scholar
• Giugliano D Maiorino MI Bellastella G Chiodini P Ceriello A Esposito K Efficacy of insulin analogs in achieving the hemoglobin A1c target of,7% in type 2 diabetes: meta-analysis of randomized controlled trials Diabetes Care 2011 34 2 510 517 21216850
   PubMed Web of Science ®Google Scholar
• Watson L Wilson BP Alsop J Kumar S Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation? Diabetes Obes Metab 2011 13 9 823 831 21481128
   PubMed Web of Science ®Google Scholar
• Ahren B Leguizamo Dimas A Miossec P Saubadu S Aronson R Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M) Diabetes Care 2013 36 9 2543 2550 23536584
   PubMed Web of Science ®Google Scholar
• Fonseca VA Alvarado-Ruiz R Raccah D Boka G Miossec P Gerich JE Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono) Diabetes Care 2012 35 6 1225 1231 22432104
   PubMed Web of Science ®Google Scholar